HLA-A — Major Histocompatibility Complex Class I A
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HLA-A — Major Histocompatibility Complex Class I A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>HLA-A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Major Histocompatibility Complex Class I A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6p21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>3105</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000206503</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P01890</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>142800</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Association</td>
</tr>
<tr>
<td class="label">HLA-A*02:01</td>
<td>Risk allele</td>
</tr>
<tr>
<td class="label">HLA-A*03:01</td>
<td>Risk allele</td>
</tr>
<tr>
<td class="label">HLA-A*24:02</td>
<td>Protective</td>
</tr>
<tr>
<td class="label">Allele</td>
<td>Caucasians</td>
</tr>
<tr>
<td class="label">A*02:01</td>
<td>~30%</td>
</tr>
<tr>
<td class="label">A*03:01</td>
<td>~20%</td>
</tr>
<tr>
<td class="label">A*24:02</td>
<td>~10%</td>
</tr>
<tr>
<td class="label">A*01:01</td>
<td>~15%</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">36 edges</a></td>
</tr>
</table>
HLA-A (Major Histocompatibility Complex Class I A) is a key gene located on chromosome 6p21.3 within the human leukocyte antigen (HLA) complex. It encodes the alpha chain of the HLA class I molecule, a cell surface glycoprotein essential for immune surveillance and antigen presentation to CD8+ cytotoxic T-lymphocytes[@klein2000][@shiina2009].
HLA class I molecules are expressed on the surface of virtually all nucleated cells and present endogenously synthesized peptide antigens to CD8+ T-cells. This process is fundamental to immune defense against intracellular pathogens ( viruses and some bacteria) and malignant transformation. Beyond this classical function, increasing evidence implicates HLA class I molecules in broader biological processes, including immune regulation in the central nervous system (CNS)[@watanabe2010][@cante2013].
The HLA-A gene is extraordinarily polymorphic, with thousands of documented alleles across global populations. This diversity has significant implications for disease susceptibility, transplant matching, and therapeutic response[@choo2007].
Gene Overview
Molecular Biology
Gene Structure
The HLA-A gene spans approximately 2.6 kb and comprises 8 exons:
- Exon 1: 5' untranslated region and signal peptide
- Exons 2-4: Encoding the three extracellular domains (α1, α2, α3)
- Exon 5: Transmembrane domain
- Exon 6: Cytoplasmic tail
- Exon 7: 3' untranslated region
Protein Structure
HLA-A encodes a transmembrane glycoprotein consisting of:
Heavy chain (~45 kDa): The polymorphic α-chain encoded by HLA-A
β2-microglobulin (~12 kDa): Non-polymorphic light chain, required for surface expression
Peptide binding groove: Forms from the α1 and α2 domains, accommodates 8-10 amino acid peptidesThe peptide binding groove has pockets (B and F being most important) that determine peptide binding specificity. Different HLA-A alleles have distinct peptide binding preferences.
Expression Pattern
HLA-A is expressed:
- Constitutively: All nucleated cells
- Inducible: Upregulated by IFN-γ, TNF-α, and other cytokines
- High expression: Immune cells (lymphocytes, monocytes)
- Brain expression: Neurons, astrocytes, microglia
Function
Classical MHC Class I Function
The primary function of HLA-A involves antigen presentation:
Peptide Processing and Loading
Intracellular proteins are degraded by the proteasome
Peptides are transported to the ER by TAP (transporter associated with antigen processing)
Peptides are loaded onto HLA-A molecules with the assistance of tapasin
The peptide-HLA-A complex is transported to the cell surfaceImmune Recognition
Surface HLA-A-peptide complexes are recognized by CD8+ T-cell receptors
This triggers cytotoxic T lymphocyte (CTL) activation
Activated CTLs can eliminate the presenting cellNon-Classical Functions
HLA-A has additional functions beyond antigen presentation[@cante2013][@morena2017]:
Interaction with NK Cells
- HLA-A interacts with killer cell immunoglobulin-like receptors (KIRs)
- Can inhibit NK cell cytotoxicity in some contexts
Signaling Functions
- HLA-A can signal through multiple receptors
- Modulates cell survival and proliferation
CNS Functions
- Regulation of neuronal development
- Synaptic plasticity modulation
- Neuroprotection
Disease Associations
Multiple Sclerosis
HLA-A alleles have been studied in [multiple sclerosis](/diseases/multiple-sclerosis)[@pashenkov2002]:
The HLA region contributes significantly to MS genetic risk, with HLA-DRB1*15:01 being the strongest individual effect.
Parkinson's Disease
HLA-A and the broader HLA class I region have been implicated in [Parkinson's disease](/diseases/parkinsons-disease) susceptibility[@boehme2018][@ham2019][@ich2021]:
Key Findings
- HLA region polymorphisms influence PD risk
- HLA-DRB1 variants show stronger associations than HLA-A
- Some HLA-A alleles may modify disease progression
Proposed Mechanisms
Alpha-synuclein presentation: HLA-A may present α-syn fragments to T-cells[@gate2019]
Microglial activation: HLA class I modulates microglial responses
Autoimmunity: Potential for α-syn-specific T-cell responses
Neuroinflammation: HLA class I influences inflammatory responsesAlzheimer's Disease
HLA class I molecules have complex roles in [Alzheimer's disease](/diseases/alzheimers-disease)[@g ao2020][@lamanna2023]:
Current Understanding
- Altered HLA class I expression in AD brain
- Potential roles in amyloid clearance
- Neuroinflammation modulation
Therapeutic Implications
- HLA class I-based immunotherapy approaches
- Modulation of antigen presentation pathways
Other Neurological Conditions
- Narcolepsy: HLA-DQB1*06:02 is primary association, HLA-A modifies risk
- Amyotrophic Lateral Sclerosis (ALS): Some HLA associations reported
- Guillain-Barré syndrome: Strong HLA associations
Non-Neurological Diseases
- Autoimmune disorders: Type 1 diabetes, rheumatoid arthritis, SLE
- Infectious disease: HIV progression, hepatitis outcomes
- Transplantation: Graft rejection, graft-versus-host disease
Genetic Polymorphism
Major Alleles
The HLA-A gene has thousands of documented alleles:
Common Alleles by Population
Allele Groups
- A*02: Most common group globally
- A*03: Common in Europeans
- A*24: Common in East Asians
- A*01: Variable by population
Therapeutic Implications
Transplantation
HLA-A matching is critical for:
- Solid organ transplantation
- Hematopoietic stem cell transplantation
- Reducing graft rejection risk
Immunotherapy
HLA-A is relevant for[@wen2024]:
- Cancer immunotherapy: Peptide vaccines targeting HLA-A
- Adoptive T-cell therapy
- Checkpoint inhibitor response
Neurodegeneration
Potential therapeutic approaches include:
- Modulating HLA class I expression
- Targeting specific antigen presentation pathways
- Immunomodulatory strategies
Brain-Specific Considerations
CNS Immune Privilege
The brain has specialized immune regulation:
- Blood-brain barrier: Limits immune cell entry
- Microglial surveillance: Resident immune cells
- Limited classical antigen presentation: Compared to peripheral immune
HLA in the Normal Brain
In healthy CNS:
- Low basal HLA class I expression
- Upregulated in disease states
- Roles in development and plasticity
HLA in Disease
Disease-associated changes include[@kang2022]:
- Increased microglial HLA expression
- Altered antigen presentation
- T-cell infiltration in some conditions
Epigenetic Regulation
DNA Methylation
HLA-A expression is subject to epigenetic regulation:
- Promoter methylation: Can repress HLA-A expression in tumors
- Tissue-specific patterns: Distinct methylation in immune vs. non-immune tissues
- Disease-associated changes: Altered methylation in neurodegenerative conditions
Histone Modifications
Chromatin states affect HLA-A:
- Active marks: H3K27ac associated with expression
- Repressive marks: H3K27me3 in silenced contexts
- Enhancer activities: Distal regulatory elements
Non-coding RNAs
microRNAs modulate HLA-A:
- miR-148a: Targets HLA-A 3'UTR
- miR-568: Downregulates HLA class I
- Let-7 family: Multiple targets in antigen presentation
Molecular Mechanisms in Neurodegeneration
ER Stress Response
HLA-A folding occurs in the endoplasmic reticulum:
Protein synthesis: Heavy chain translation in ER
Quality control: Calreticulin/calnexin system
peptide loading: TAP-mediated peptide transport
Surface expression: Golgi processing and traffickingER stress affects HLA-A processing in neurodegeneration.
Autophagy Interplay
Autophagy and HLA-A intersect:
- Cross-presentation: Autophagy delivers antigens to HLA class I
- IFN-γ effects: Autophagy required for optimal presentation
- Disease relevance: Altered autophagy in neurodegeneration
Neuroimmune Signaling
The neuroimmune axis involves HLA-A:
- Microglial activation: Triggered by antigen presentation
- T-cell infiltration: CD8+ T-cells in PD/AD brain
- Cytokine effects: IFN-γ modulates HLA expression
Research Directions
Current Areas of Investigation
Genetic studies: Population-specific HLA effects
Functional studies: Mechanism of HLA-associated risk
Therapeutic development: HLA-targeting approaches
Biomarkers: HLA as disease biomarker
Single-cell analysis: Cell-type specific expressionFuture Directions
- Personalized medicine applications
- Gene therapy approaches
- Immunomodulation strategies
- Epigenetic therapies
- CAR-T cell approaches for neurodegeneration
Interaction Networks
Receptor Interactions
HLA-A interacts with multiple receptors:
T-cell Receptor (TCR): Primary interaction
- CD8+ T-cell recognition
- Activation of cytotoxic response
Killer Cell Immunoglobulin-like Receptors (KIRs)
- NK cell regulation
- Inhibition or activation
CD8 Co-receptor
- Enhances TCR engagement
- Required for optimal signaling
Peptide Presentation
HLA-A presents diverse peptides:
- Viral peptides: From infected cells
- Tumor antigens: Cancer-specific peptides
- Self-peptides: Normal cellular proteins
- Mutated peptides: Cancer-associated variants
Clinical Considerations
HLA Matching
Transplantation requires HLA-A matching:
Donor-recipient matching: Minimize rejection
Desensitization protocols: For mismatched transplants
Virtual crossmatching: Pre-transplant assessmentDisease associations
Beyond neurodegeneration:
- Type 1 Diabetes: Strong HLA-DR association
- Rheumatoid Arthritis: HLA-DR specific
- Systemic Lupus Erythematosus: Multiple loci
- Celiac Disease: HLA-DQ specific
Research Methods
Detection Methods
- Serology: Traditional typing
- Sequence-based typing (SBT): DNA sequencing
- Flow cytometry: Cell surface expression
- Mass spectrometry: Peptide identification
Animal Models
- Transgenic mice: HLA-A expression
- Knockout models: Loss of function studies
- Humanized mice: Immune system models
Summary
HLA-A represents a critical intersection between adaptive immunity and neurodegenerative disease. Its role in antigen presentation, immune regulation in the CNS, and genetic associations with disease risk make it an important target for understanding neurodegeneration. Key implications include:
- Disease risk: HLA alleles modify neurodegenerative risk
- Immune modulation: Class I pathways in neuroinflammation
- Therapeutic potential: Targeting antigen presentation
- Biomarker development: HLA as disease marker
Further research into HLA class I biology will provide insights into neurodegenerative disease mechanisms and potential therapeutic approaches.
See Also
- [Major Histocompatibility Complex](/entities/mhc)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Microglia](/cell-types/microglia)
External Links
- [NCBI Gene: HLA-A](https://www.ncbi.nlm.nih.gov/gene/3105)
- [UniProt: HLA-A](https://www.uniprot.org/uniprot/P01890)
- [IMGT/HLA Database](https://www.ebi.ac.uk/ipd/imgt/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
References
[Klein & Sato, The HLA system (2000)](https://pubmed.ncbi.nlm.nih.gov/10974132/)
[Shiina et al., HLA complex: from gene to function (2009)](https://pubmed.ncbi.nlm.nih.gov/19301028/)
[Choo, The HLA system: genetics and disease association (2007)](https://pubmed.ncbi.nlm.nih.gov/17580788/)
[Pashenkov et al., HLA in multiple sclerosis (2002)](https://pubmed.ncbi.nlm.nih.gov/11872614/)
[Watanabe et al., HLA class I and immune regulation in the brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20699246/)
[Cante et al., HLA class I molecules couple to multiple receptor tyrosine kinases (2013)](https://pubmed.ncbi.nlm.nih.gov/24227734/)
[Morena et al., The emerging role of HLA class I in neurodegenerative disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28361916/)
[Boehme et al., Microglial HLA-DR and CD4 T cells in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29594288/)
[Gate et al., HLA genotype influence on alpha-synuclein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/31185892/)
[Gao et al., HLA class I in Alzheimer's disease brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32303325/)
[Ham et al., HLA-DRB1 and Parkinson's disease risk (2019)](https://pubmed.ncbi.nlm.nih.gov/30626653/)
[Ich et al., Common genetic variation in HLA region affects PD risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34134982/)
[Kang et al., HLA class I-mediated neuroprotection in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35817342/)
[Lamanna et al., HLA expression in microglia (2023)](https://pubmed.ncbi.nlm.nih.gov/37093421/)
[Wen et al., Targeting HLA-class I pathways for neurodegenerative disease therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/39182847/)